Hoya Pentax expanded into the endoscopic therapy market
in September through the strategic investment in electrosurgical devices company Creo Medical Ltd. Pentax identified endoscopic therapeutic devices as a priority in its growth strategy,
and grants the division access to an electrosurgical platform.
Hoya’s flexible endoscopes—which are used in minimally invasive treatment procedures—will be combined with Creo
Medical’s therapeutic devices in such areas as highly advanced
gastroenterological surgeries. Pentax also launched the Splash
M-Knife multi-functional Endoscopic Submucosal Dissection
(ESD) device in May 2015. ESD procedures are gaining world-wide interest and adoption for their clinical and financial benefits contributing to early recovery, reduced procedural complexi-ties, and costs. The new ESD device will contribute heavily to
the early treatment of gastric cancer.
Hoya’s IOL business was the largest growth area for the company in fiscal 2016, achieving 23 percent revenue growth from
the previous year. This was mainly stimulated by introduction of
aspherical IOLs into the major markets including both European
and Japanese, the latter of which represented half of Hoya’s IOL
sales. The new IOLs are made of“Vivinex,” Hoya’s newly developed hydrophilic acrylic material. Vivinex builds on Hoya’s original surface reforming treatment, and the lenses are anticipated to
curtail the appearance of posterior capsule opacification, a complication that causes the back of a lens capsule to thicken, causing
cloudy vision. The IOLs made of Vivinex are currently undergoing
a series of clinical evaluations to gain additional patient trust.
Furthering its commitment to surgical vision care, in October
2015 Hoya revealed late-stage venture investment in InnFocus
Inc., a Miami-based company developing the InnFocus MicroS-hunt to treat open angle glaucoma. A tube less than 1 cm in length
designed to lower intraocular pressure in open angle glaucoma
patients, it is composed of a soft, biocompatible material that minimizes tissue damage and significantly reduces operation time.
Hoya Pentax also welcomed a new leader in February 2016,
appointing Hoya veteran Gerald Bottero as global president of
the division. Bottero joined Hoya in 1988, serving as representative on the Boards of Directors of Hoya’s Decibel Instruments
(intra-canal hearing aids) and Lifespex Inc. (early detection of
cervical cancer), president of Hoya Conbio (a medical laser firm
focused on dermatology and hard tissue dentistry), and the president of Hoya Vision Care from 2005 to 2014.
“I am truly honored to support the richly talented and highly
dedicated global professionals of Pentax Medical,” Bottero said in
a company statement. “Our mission is to ‘lead the leading edge’
in intelligent, software-rich endoscopic solutions for the early
detection and treatment of cancer. Patients comprise the center
of our universe; every day in every way, our job is to help doctors, nurses and biomeds improve the quality of patients’ lives.
We are very excited about our opportunities, and by the enthusiastic feedback we have received from customers regarding new
technologies we are developing for interactive imaging, single-use devices, mobility, and scalable platforms.”
29. Hologic Inc.
Stephen P. MacMillan, Chairman, President, and CEO
Robert W. McMahon, CFO
Eric B. Compton, COO
Michael Davin, Division President, Cynosure
Thomas P. O’Neill, Division President, GYN Surgical Solutions
Peter J. Valenti III, Division President, Breast and Skeletal Health
Thomas A. West, Division President, Diagnostics Solutions
NUMBER OF EMPLOYEES: 5,333
GLOBAL HEADQUARTERS: Marlborough, Mass.
After being diagnosed with breast cancer in 2006, singer/ songwriter Sheryl Crow continues to raise her voice in search for a cure. In June 2016, almost 10 years since
her diagnosis, she became the national spokesperson to educate
women about The Genius 3D Mammography exam, Hologic’s
breast cancer exam proven to detect the disease 15 months earlier
than traditional 2D exams.
“Early detection saves lives—it’s that simple,” Crow said in
Hologic’s announcement of her spokesperson role. “Women
need to be advocates for their health, and that means getting annual mammograms starting at age 40 and taking advantage of
the best, and most accurate, technologies available. I opted for a
Genius exam because early detection is what saved my life—it’s a
woman’s best chance at survival, and it’s a chance we all deserve.”
In addition to digital mammography systems like Genius 3D,
Hologic’s Breast Health portfolio includes a number of technologies to aid early diagnosis like computer-aided detection for
mammography, minimally invasive breast biopsy devices, breast
biopsy site markers, and breast biopsy guidance systems. With
fiscal year 2016 revenue (ended Sept. 24, 2016) of $720 million—
up 5 percent from the year prior—the segment contributed a
quarter of Hologic’s $2.8 billion in revenue, which was also a 5
percent increase from 2015.
The bump was almost entirely a result of higher worldwide
sales of the company’s 3D Dimensions digital mammography
systems, which rose $57 million from 2015. The growth was also
partly a result of increased sales of C-View, the software powering Hologic’s Low Dose 3D Mammography exam. Diminished
sales of the 2D Selenia system and interventional breast solutions products and no sales of the MRI breast coil line (which
was discontinued in 2015) did not offset the emboldened digital mammography sales. Further expanding the Breast Health
product mix, in April 2016 Hologic launched its U.S. Food and
Drug Administration (FDA)-cleared Affirm Prone Biopsy System, the first 2D/3D imaging-guided dedicated prone biopsy